Macrocyclics and Constrained Peptides icon  

Fifth Annual

Macrocyclic and Constrained Peptides

Bigger, Better and Still Oral Small Molecules

April 25-26, 2017

The relatively new class of drug-like compounds – synthetic macrocyclics and constrained peptide therapeutics -- are garnering great interest in the drug development industry because of their mix of favorable properties. Their middle size (.5 -2kilodaltons) ensures they are small enough, unlike biologics, to cross the cell membrane and reach intracellular PPI and traditional targets. Yet these molecules have the safety/tolerability advantage of biologics because they are bigger than typical 'small molecule' drug agents and therefore capable of more specific interactions with their targets. The cyclic nature of macrocyclics and constrained peptides affords stability and the potential to be developed into oral-based medicines. However, while there are a few macrocyclic or constrained peptide compounds progressing in clinical trials, one has yet to reach the market. This meeting covers the technological advances that are enabling these compounds to progress and addresses the challenges that still remain.

Topics will include, but are not limited to:

  • DNA-encoded small macrocylic or constrained peptide libraries
  • Peptide cyclization strategies – combining biologic and chemical approaches
  • Scaffolds for macrocyclics for different drug applications
  • Design guidelines for ‘drug-like’ macrocyclic libraries/beyond the rule of five
  • Solubility and cell permeability challenges
  • Case studies on synthetic macrocyclics or constrained peptides proceeding in development
  • Optimization challenges of synthetic macrocyclics or constrained peptides

If you would like to submit a proposal to give a presentation at this meeting, please click here.

The deadline for submission is October 7, 2016.

All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

We hope you can join us for this day-and-a-half conference (one of four parallel tracks) that is in the second half of our larger Drug Discovery Chemistry event. Attending this meeting enables you to also hop to concurrent meeting tracks to hear other presentations of interest.

For more details on the conference, please contact:
Anjani Shah, Ph.D.
Conference Director
Cambridge Healthtech Institute
Phone: (+1) 781-247-6252

For partnering and sponsorship information, please contact:
Carolyn Benton
Business Development Manager
Cambridge Healthtech Institute
Phone: (+1) 781-972-5412